The thiazolidinedione PPARγ agonist Pioglitazone (PIO) stimulates hepatic fatty acid oxidation and improves insulin sensitivity and reduces steatosis in NAFLD patients [29,30]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.